EP0551320A1 - Protein produced from hirudo medicinalis - Google Patents

Protein produced from hirudo medicinalis

Info

Publication number
EP0551320A1
EP0551320A1 EP19910916983 EP91916983A EP0551320A1 EP 0551320 A1 EP0551320 A1 EP 0551320A1 EP 19910916983 EP19910916983 EP 19910916983 EP 91916983 A EP91916983 A EP 91916983A EP 0551320 A1 EP0551320 A1 EP 0551320A1
Authority
EP
Grant status
Application
Patent type
Prior art keywords
protein
ml
ph
new
hirudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910916983
Other languages
German (de)
French (fr)
Inventor
Siegfried Bialojan
Karl-Hermann Strube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

L'invention concerne une nouvelle protéine extraite d'hirudo medicinalis qui prolonge le temps de coagulation du sang, qui est relativement stable à la chaleur et qui a un poids moléculaire compris entre 25 et 34 KDa, ainsi que ses mutéines, utiles pour traiter des maladies. The invention relates to a new protein derived from Hirudo medicinalis, which extends the blood coagulation time, which is relatively stable to heat and which has a molecular weight between 25 and 34 KDa, as well as muteins thereof, useful for treating diseases.

Description

Protein from Hirudo medicinalis

description

The present invention relates to a novel protein from the leech Hirudo medicinalis, its muteins and their Her¬ position and use.

a number of medically interesting factors have been described that play a role in areas such as blood coagulation and fibrinolysis from the secretions of various flukes. These factors include fibrinolytic agents which degrade fibrin or fibrinogen directly and Plas activators inogen-. To the fibrin or fibrinogen-depleting substances include the hementin (of He enteria ghilianii) and the de stabilase (Hirudo medicinalis from; IP Baskova et al Folia Huh atol, Leipzig, 115, 1988, p.166..). A plasminogen activator described in secretions of Hementeria depressa.

Next also inhibitors of clotting, such are the thrombin bininhibitor hirudin (Hirudo medicinalis from), a factor Xa-in hibitor (Hirudo medicinalis out), trypsin and plasmin and chymotrypsin and elastase inhibitors such as the Bdellin or eglins described (Hirudo medicinalis out) (Leech Biology and Behavior, Vol. II, Oxford, Science Publication / RT Sawyer, 1986).

It has now been isolated from Hirudo medicinalis a new factor.

The invention relates to a novel protein from Hirudo medi¬ cinalis that prolongs the clotting time of the blood, is relatively heat stable and has a molecular weight of 25 to 34 kDa be¬ sits, and its muteins.

The novel protein prolongs the intrinsiche clotting time (APTT) and extrinsic coagulation time (PT) of the blood significantly. It differs in its coagulation-retardant properties are of hirudin and the factor Xa inhibitor. In fractions in which the APTT prolonging activity is present, neither appropriate amounts of hirudin (by ELISA) or factor

Xa inhibitor activity be detected (by color substrate). As muteins of the new protein, such proteins are understood to be derived from the new protein by substitution, deletion and / or addition of amino acids or peptides without their properties differ greatly lower the new protein.

The new protein can be from leeches (Hirudo medicinalis) win. To this end, the leeches are placed in water. After stimulation with arginine leeches enter the factor into the watery solution from which the new protein chromatography or in a known manner by ion exchange, affinity, gel permeation chelating and is isolated by hydrophobic chromatography.

You can dot the leeches after arginine stimulation and isolate the novel protein as described above from the puncture.

It is also possible to purify the new protein from the homogenate of heads dekapitierter flukes in an analogous manner.

To the protein for therapeutic purposes in large quantities to make ver¬ fügbar, can be known genetic engineering techniques (see Maniatis, T. et al, Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Press, NY, 1989) apply. For this purpose, the protein is first produced in pure form. Subsequently, the protein is digested and the resulting peptides fractionated by reversed phase HPLC (RHPLC). Some of these peptides, the amino acid sequence is determined. With oligonucleotides derived from the determined sequences, the gene coding for the novel protein is then identified in a c-DNA library by sequence-specific hybridization filter. The genetic information thus obtained can then be put in various host cells by known methods for expression. To the expression rate pressionssystemen one hand prokaryotes such as E. coli or Bacillus subtilis, but also eukaryotes such as yeast and mammalian cells include (for example CL27 mouse fibroblasts, hamster, Insekten¬ cells).

The new protein and its muteins are useful for treating diseases, particularly for treatment and prophylaxis of thrombotic conditions. Be i sp i el

a) extraction of Egelextrakt

Extracts of Hirudo medicinalis were obtained go to the following Ver¬:

1. flukes were treated 75 min with a 10 mM arginine solution. During this time, the solution adopted by the secretory activity of the leech on a yellowish color.

After exchange of the liquid against water leeches further secreted.

2. leeches who had been first treated in accordance with arginine were punctured and won the stomach contents.

b) Purification of the new protein.

The liquids obtained in a) were individually or together for 10 minutes at 90 ° C and then cooled immediately on ice. After centrifugation (20 min, 10,000 rpm, Sorvall® SA 600 rotor) the supernatant was initially 1: 2 to 1: 5 diluted with PBS. The pH was adjusted to 7.4. The solution was then equilibrated in a PBS

Q-Sepharose® column (10 ml, Pharmacia, Sweden). After washing away unbound material, the column with a linear gradient of 0 to 100% buffer A (PBS + 1 M NaCl) was eluted. Aliquots of the fractions were assayed for APTT prolongation. The new factor eluted under these conditions is between 0.3 M and 0.5 M NaCl.

Fractions containing activity were combined, 1: 2 with 20 mM phosphate buffer, 250 mM NaCl pH 7.0 is diluted and loaded onto a Cu Chelating column (1 ml). After rinsing with 10 to 15 column volumes of equilibration buffer (20 mM NaPhosphate, 250 mM NaCl pH 7.0), elution was carried out by applying a linear gradient of 0 to 100% buffer B (20 mM succinic acid, 1 M NaCl pH 4.0) , The column was then nacheluiert with either 20 mM phosphate, 2 M NaCl, 10 mM EDTA, pH 7 or 20 mM succinic acid 2 M NaCl, 100 M histidine pH. 4 Aliquots of individual fractions fractions were assayed for APTT prolongation containing activity pooled and Centricon 10 (A icon, Cat. No. 4206), concentrated, buffer exchanged to PBS and on a FPLC Gelfilrationssäule (Superose® 12, Pharmacia) at a flow rate 0.5 ml / min purified further.

The fractions containing activity were pooled and applied to a column equilibrated with PBS mono Sepharose® (Pharmacia, Sweden). From the Mono Q column, the elution was carried out either with a pH gradient (0 to 100% B, Buffer B = 20 M succinic acid 1 M NaCl pH 4) or with a salt gradient (0 to 100% buffer A).

S-Sepharose chromatography

For further purification of the new factor chromatography on S-Sepharose (LKB, Pharmacia) was carried out. For this purpose the value of fractions of the Q-Sepharose or Cu-chelating chromatography initially using a concentrate chamber (Amicon, YM 10 membrane) at pH 4 or 7 and onzentriert by repeatedly filling and concentrating desalted.

After the final step, the concentrates were diluted to 20 mM succinic acid pH 2.5 (final concentration) and applied to a column equilibrated with 20 mM succinic acid pH 2.5 S-Sepha- rose-Säule®. possibly existing hirudin was separated by elution with 30 mM of succinic acid pH 4.5. The elution of the new factor? was performed by applying a buffer gradient by PE pH 7.5. In the value of the S-Sepharose fractions to a pH of 5.5 was - 7 measured. The fractions containing activity (thrombin inhibition) were further containing a hirudin Elisa (s. Example 6a) were tested. Fractions which prolong the APTT and were negative in the hirudin Elisa were combined, aufkonzen¬ trated, evaporated to dryness, taken up in ammonium acetate pH 6 by RHPLC on a C-4 phase (rp 304® Bio-Rad) purified further. Reversed phase HPLC (RHPLC)

The thrombin inhibition fractions comprising the S-Sepharose chromatography were further purified by reversed phase HPLC on a Bio-RAD rp304® column with a 20 M ammonium acetate, pH 6, 20 M ammonium acetate, 50% Acetonitri 1 system , For this, the fractions were concentrated to a volume of 200 to 500 .mu.l and eluted by applying a gradient of acetonitrile from RHPLC. The new factor elusiert at a Acetonitri Ikonzentration of 7.5% + _ 3%. The activity of the new Thrombininbibitors is retained and can be detected by Tricine-SDS-polyacrylamide gel electrophoresis or APTT determination.

c) Characterization of the new protein

1. Temperature stability

An aliquot of the new factor was heated for 10 min at 95 ° C and then immediately cooled on ice. The activity was determined by measuring the inhibition of the APTT. By the heat treatment, the activity decreased by about 10%.

2. solvent stability

An aliquot of the sample containing activity was added at room temperature with 50% acetonitrile in 20 M ammonium acetate pH 6.0 and incubated for 30 min. After removing the solvent, the influence of the sample was analyzed for APTT. It turned out that the new factor is not influenced in its activity by acetonitrile.

3. Protein Nature

An aliquot of the new factor was incubated with 10 ug trypsin for 16 h at 37 ° C. The reaction was stopped by boiling for 5 minutes and immediately cooling with ice and thereafter determines the influence of the sample to the inhibition of the APTT. It has also been moved to a control sample that was not otherwise treated equally with trypsin. The Ergeb¬ Results show that after incubation with trypsin, the activity of factor disappears, proving its protein nature. 4. Molecular Weight

a) The molecular weight of the new protein was limited defined using membranes pore size. For this purpose, fractions containing the new protein were incubated with buffer (PBS pH 7.2 or 20 mM succinic acid pH 4), washed in a Centricon® microconcentrator (10 and 30 kDa Ausschlu߬ limit) and 60 min at 5000 xg centrifuged. The runs of the membranes were in a Speed ​​Vac Concen- trator to dryness, resuspended in PBS and likewise as are the residues of the membranes in the APTT measured.

At both pH values, the new protein made by Centricon 10, focused but not by Centricon 30th This means that the novel protein should have a molecular weight of 10-30 kDa.

b) The molecular weight was determined next (on a calibrated gel filtration column Superose 12). while PBS was used as eluent at a flow rate of 0.3 ml / min. There were

fractionated fractions of 150 ul and assayed for APTT prolongation. The maximum activity was determined under these conditions Bedin¬ to 34 kDa in a range of 25 kDa.

c) Determination of molecular weight by Tricine-SDS-polyacrylamide gel electrophoresis

The gel electrophoresis was performed according to the procedure (Schagger, H. and von Jagow, G .; Analytical Biochemistry, 166, 368-379 (1987) at 20 A and 1400 V, 30 W, with a power company LKB, and an overflow chamber of the " mighty s performed all system ". After completion of the electrophoresis, the gel was incubated X100 and then to a thrombin and fibrinogen-containing agarose plate 2 firstly for 30 minutes in a 2.5% solution of Triton times

issued 20 minutes. The concentration of thrombin in the agarose was adjusted such that polymerization of the fibrinogen took place within 2 to 4 hours under the action of thrombin. The presence of the new thrombin inhibitor was by unpolymerized places in the

Agarose displayed. (By staining the molecular weight marker calibration proteins: Intact Myoglobin 17.2 kDa, myoglobin I + Bromcyanpeptid Uli 14.6 kDa, myoglobin I Bromcyanpeptid 8.2 kDa, myoglobin II Bromcyanpeptid 6.4 kDa, myoglobin III Bromcyanpeptid 2.6 kDa, myoglobin 1 -14), the Molekular¬ weight of the new thrombin inhibitor with 14 6 + _ 3 kDa determined.

5. point of application of the new protein in the coagulation cascade

The new factor was overall in various assay systems tested to determine how and which factors in the coagulation as (he ade inhibited.

a) APTT (activated partial thromboplastin time ***) for Nach¬ facing an anticoagulant activity in the intrinsic coagulation cascade see.

human plasma (eg Preciclot®, Boehringer / Ma, no. 654370) was diluted samples to be tested in 50 ul. For this purpose, a 50 ul PTT reagent (Boehringer / Ma, no. 886 050) was pipetted and incubated for 5 min at 37 ° C. By adding 50 ul 25 mM CaCl the coagulation cascade has started. the time was measured until the occurrence of clots Plasma¬.

The samples showed a significant prolongation of plasma clotting time (intrinsic).

b) PT (= prothrombin time, Quick-Test) for detecting an anticoagulant effect on the extrinsic coagulation cascade.

Samples were resuspended in 100 ul human plasma (eg Preciclot®, Boehringer / Ma, no. 654370) diluted. To this was added 100 .mu.l of thromboplastin (1: 1 with NaCl 0, 9% diluted) were pipetted. With 50 ul of 25 mM CaCl 2, the coagulation cascade has started. the time was measured until the occurrence of clots Plasma¬. The samples showed a significant Ver¬ prolongation of plasma clotting time (extrinsic). c) FXa inhibition assay for differentiation of FXa inhibitor

Samples (diluted in PBS) were incubated with factor Xa (FXa) and a specific chromogenic substrate for FXa 60 min at room temperature:

25 ul of sample

50 ul FXa (Boehringer / Ma, no. 602,388, 0,025 U / ml) 100 ul S-2222 chromogenic substrate (Kabi Vitrum-, 16.9 ml H 2 0 / vial) After 5 minutes, the optical density at 405 nm first measured. After 60 min the reaction was stopped with 50 .mu.l of glacial acetic acid and the optical density at 405 nm is measured again.

As controls approaches without FXa and samples are used without inhibitor. For the evaluation, a Δ OD 405 was 40 'is calculated using the following formula:

Δ OD = CθD 60m-OD5 min] + FXa - [OD OD 5minJ' 0min- 6-FXa

(Difference in absorbance with and without FXa).

From respective batches with and without inhibitor, the degree of inhibition of FXa is given by (in%)

Δ 0D + inhibitor

% Inhibition = 100 x

Δ 0D -lnhibitor

d) thrombin time

A sample of the new protein was diluted in 100 .mu.l ver¬ plasma. By adding 50 ul thrombin reagent (Boehringer / Ma, no. 126 594) was started clotting. The time to onset of plasma clots was determined turbine-do etrisch.

The evaluation was performed using a calibration curve with known thrombin inhibitors (eg, hirudin). The results of obtained show that the new protein is a thrombin inhibitor. 6. Attempts to define the new protein to hirudin

a) fractions of the new protein, the ATU showed an APTT prolongation according 2500, were introduced into a Hirudin ELISA:

Material:

Microtiter plates (Flow 77-173-05) - streptavidin-peroxidase Ko plex (Boehringer / Ma 1,089,153) tetramethylbenzidine (Serva 35926) Peroxidase substrate: 0.1 ml TBM solution (42 mM in DMSO TBM) and 10 ml of substrate buffer (0, M Na-acetate pH 4.9) to mix slowly 1; then addition of 14.7 .mu.l of 3% H2O2

procedure:

Coat microtiter plates with 0.2 ml / well hirudin

(1 ug / ml, in 0.1 M NaHC0 3, pH 8.3) - saturate with 1% BSA / PBS; 0.3 ml / well

Wash 3x with 0.05% Tween 20 / PBS

12 standard dilutions of hirudin, starting with

500 ng / l 0, 1% BSA / PBS in 2-steps, of which each

0.1 ml / well; then addition of 0.1 ml / well poly-anti-hirudin (1 ug / ml 0.1% BSA / PBS) and

Overnight incubation / 4 ° C

Washing as above,

0.2 ml / well biotinylated anti-rabbit IgG anti-body (1: 5000) for 2 h at room temperature, - washing as above,

0.2 ml / well streptavidin-peroxidase complex (1: 10,000);

30 min at room temperature

Washing as above,

0.1 ml / well peroxidase substrate - stop reaction with 0.1 ml / well 2M H 2

Measuring the absorbance at 450 nm

Evaluation:

The obtained OD values ​​were plotted against the logarithm of

Standard dilutions were applied and in the range of about 60 to 2 ng / ml, a linear dependence. Samples of unknown concentration of hirudin is set parallel to the calibration sample in different dilutions in a test. In the measured samples, hirudin was detected, which corresponds to an activity of maximum 5 ATU / ml.

b) thrombin time (= TZ)

In the analysis of the new protein, the measurement of TZ gave a antithrombin activity 200 ATU / ml. This value was a factor of> 40 over by ELISA for hirudin er¬ mediated value. This proves that the new protein is hirudin.

c) concentration

An attempt was made to focus hirudin using Centricon membranes at p and the seventh Hirudin was not retained by the Centricon 10-Memb. The new protein is retained under these Condition E of the membrane (see FIG. 4a).

Claims

claim
Protein from Hirudo medicinalis, which prolongs the clotting time of the blood, is relatively heat stable and has a molecular weight of 25 to 34 kDa, and its muteins.
EP19910916983 1990-10-06 1991-09-27 Protein produced from hirudo medicinalis Withdrawn EP0551320A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE4031731 1990-10-06
DE19904031731 DE4031731A1 (en) 1990-10-06 1990-10-06 Protein from hirudo medicinalis

Publications (1)

Publication Number Publication Date
EP0551320A1 true true EP0551320A1 (en) 1993-07-21

Family

ID=6415763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910916983 Withdrawn EP0551320A1 (en) 1990-10-06 1991-09-27 Protein produced from hirudo medicinalis

Country Status (5)

Country Link
EP (1) EP0551320A1 (en)
JP (1) JPH06501255A (en)
CA (1) CA2093432A1 (en)
DE (1) DE4031731A1 (en)
WO (1) WO1992006118A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0209061B1 (en) * 1985-07-17 1994-01-12 Hoechst Aktiengesellschaft Peptides having an anticoagulant activity, process for their preparation, obtention, their use and agents containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9206118A1 *

Also Published As

Publication number Publication date Type
WO1992006118A1 (en) 1992-04-16 application
CA2093432A1 (en) 1992-04-07 application
DE4031731A1 (en) 1992-04-09 application
JPH06501255A (en) 1994-02-10 application

Similar Documents

Publication Publication Date Title
Esnouf et al. The isolation and properties of the thrombin‐like activity from Ancistrodon rhodostoma Venom
Wulf et al. Studies on plasminogen. VIII. Species specificity of streptokinase
Nossel et al. Inhibition of Hageman factor activation
Furlan et al. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
Niléhn Separation and estimation of split “products” of fibrinogen and fibrin in human serum
Mimuro et al. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor
Müller-Esterl et al. Kininogens revisited
Hayes et al. Induction of target cell DNA release by the cytotoxic T lymphocyte granule protease granzyme A.
Nesheim et al. Isolation and characterization of single chain bovine factor V.
Kane et al. Factor Va-dependent binding of factor Xa to human platelets.
Plow et al. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH.
Broze et al. Human Protein Z.
Kaplan et al. The fibrinolytic pathway of human plasma: isolation and characterization of the plasminogen proactivator
Roldan et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
Preissner et al. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin.
Higuchi et al. The effect of leukocyte elastase on tissue factor pathway inhibitor
Andersson et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration
Sakai et al. A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I.
Elrod et al. Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep
Olexa et al. Evidence for four different polymerization sites involved in human fibrin formation
Funakoshi et al. Human placental anticoagulant protein: isolation and characterization
Vlasuk et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis
Fenton et al. Human thrombins. Production, evaluation, and properties of alpha-thrombin.
Chandra et al. Sequence homology between human. alpha. 1-antichymotrypsin,. alpha. 1-antitrypsin, and antithrombin III
Koppelman et al. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 19930108

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE

18W Withdrawn

Withdrawal date: 19930819

R18W Withdrawal (correction)

Effective date: 19930819